ICU (33) PLSM (48) SINT (37) GUTS (52) ⌘ Pro Terminal →

Femasys Inc. (FEMY) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell FEMY stock right now?

Femasys Inc. (FEMY) currently earns a Roarable Rating of D- (Sell — SELL) with 35/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is FEMY's 12-month price target and RQD AI Jury consensus?

FEMY's 12-month base price target is $1.22 (range $0.95 to $23.31), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.36 -3.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Femasys Inc. (FEMY) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $11.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FEMY)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMOVERSOLD (<32)

27.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.36H: $22

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on FEMY

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 62.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like FEMY

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FEMY)

✓Walkthrough of FEMY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FEMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.37%⚡ TESTING RESISTANCE

2026-10-30O $1.33H $1.41L $1.30C $1.36VOL 95.1K

RES: $2.01SUP: $1.31SMA50: $2.29SMA200: $6.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FEMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FEMY Butterfly Map → + Track FEMY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +40.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FEMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FEMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FEMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FEMY)

Health Care Rank #829 of 1016 ⚔️ ICU vs FEMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FEMY vs. ICU, PLSM, SINT, GUTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Femasys Inc. (FEMY) ranks #829 by composite RQD confidence (35/100, grade D-) and #885 by equity capitalization ($11.3M). Within this direct 5-issuer industry benchmark cohort, FEMY leads on earnings valuation at N/A trailing P/E, while FEMY leads on capital efficiency and profitability with -35.0% ROIC and 62.0% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with FEMY at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FEMY ACTIVE Femasys Inc.	D-	35/100	—	62.0%	-35.0%	-3.90%	$11.3M	Benchmark Subject
ICU SeaStar Medical Holding Corporation	E	33/100	—	95.7%	-35.0%	-6.85%	$12.2M	/icu-vs-femy →
PLSM Pulsenmore Ltd.	D	48/100	—	—	—	-8.48%	$10.5M	/plsm-vs-femy →
SINT SiNtx Technologies Inc.	D-	37/100	—	45.3%	-35.0%	-1.15%	$13.0M	/sint-vs-femy →
GUTS Fractyl Health Inc.	D+	52/100	—	—	-35.0%	+11.40%	$13.2M	/guts-vs-femy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001339005

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Femasys Inc. (FEMY) reported GAAP revenue of $2.3M (+40.8% vs. FY2024 revenue of $1.6M , and +113.9% cumulative change since FY2023) , GAAP net income of -$18.6M, operating cash flow of -$18.7M, and free cash flow of -$19.2M (+4.9% YoY). On the balance sheet, FEMY closed FY2025 with $20.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.3M	-$18.6M	-$18.7M	-$19.2M	$20.7M	—
FY2024 (FY)	2024-12-31	$1.6M	-$18.8M	-$19.4M	-$20.2M	$12.4M	—
FY2023 (FY)	2023-12-31	$1.1M	-$14.2M	-$11.3M	-$11.3M	—	—

3. FEMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FEMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Femasys Inc. (NASDAQ: FEMY) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.36 (-3.90% 1D, market cap $11.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FEMY ranks #829 in composite RQD confidence.

How does FEMY compare to ICU and PLSM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), FEMY carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, ICU (SeaStar Medical Holding Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $12.2M) and PLSM (Pulsenmore Ltd.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $10.5M). Among the 5-stock peer group, FEMY leads on earnings multiple (N/A) while FEMY leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FEMY?

Per FEMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339005), Femasys Inc. generated $2.3M in revenue (+40.8% YoY), -$18.6M in net income, and -$19.2M in free cash flow against $20.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FEMY trading relative to its 50-day, 200-day, and 52-week technical levels?

FEMY last traded at $1.36 (-3.90% on volume of 110,317 shares), positioning the stock -40.61% below its 50-day simple moving average ($2.29) and -77.81% below its 200-day simple moving average ($6.13). Across its 52-week range of $1.30 to $22.20, FEMY sits at the 0.3% percentile with a 14-day RSI of 27.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.19 to $1.53).

FEMY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell FEMY stock right now?

Femasys Inc. (FEMY) currently earns a Roarable Rating of D- (Sell — SELL) with 35/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is FEMY's 12-month price target and RQD AI Jury consensus?

FEMY's 12-month base price target is $1.22 (range $0.95 to $23.31), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: FEMY RQD Cockpit FEMY 12M Forecast FEMY Earnings & Move FEMY Dividends & DRIP FEMY Insiders & 13F FEMY Whale Options FEMY Profit Sankey FEMY News & Why